Endocrine Abstracts

JOINT2646

Introduction: In treatment of central precocious puberty (CPP) girls, existing literatures suggest that stopping treatment around a bone age (BA) of 12 years may result in the most favorable adult height, but there are few real-world studies that compare the effects of BA at the time of treatment cessation on final adult height. Therefore, we investigated whether the differences of BA at treatment cessation significantly influence near adult height (NAH).

Methods: A retrospective study was conducted on 117 CPP girls treated with GnRH agonists. Patients were followed up until their BA was 13 years or older after treatment cessation. Predicted adult height (PAH) at treatment initiation and NAH at the last visit were calculated using the Bayley-Pinneau method. This study compared growth outcomes across three groups classified by BA at treatment cessation (’11.5 year’, ’12 year’, ‘≥12.5 year’) and assessed correlations between several clinical factors and NAH outcomes.

Results: Mean chronological age (CA) at treatment initiation was 8.4 years, and mean BA at treatment initiation was 10.1 years. Differences between BA and CA (BA-CA) at treatment initiation were 1.37 year in the 11.5 year group, 1.78 year in the 12 year group, and 2.05 year in the ≥12.5 year group (p<0.001). Predicted adult height (PAH) at treatment initiation were 159.16 cm, 160.03 cm, and 156.82 cm, respectively (p<0.05). NAH of each group were 163.89 cm, 164.64 cm, and 163.28 cm, respectively (p=0.423), and differences between PAH at treatment initiation and NAH (NAH-PAH) were 4.73 cm, 4.61 cm, and 6.46 cm, respectively (p<0.05). Multivariate regression analysis showed significant positive associations of NAH with MPH, height SDS at treatment initiation and cessation, and negative association with the difference between BA and CA at treatment cessation.

Conclusion: Our findings suggest that even patients with markedly advanced BA at the start of treatment could achieve comparable NAH if the treatment duration is sufficiently prolonged. So individualized treatment plans considering BA advancement and height at the end of treatment are essential for the best growth outcomes in CPP patients.